Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status:
Not yet recruiting
Trial end date:
2032-06-01
Target enrollment:
Participant gender:
Summary
Background:
Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the
United States. People with HIV are up to 17 times more likely to get NHL than people who do
not have HIV. The disease may also be different in these two groups. More study is needed for
treating
people with both HIV and NHL.
Objective:
To test a study drug (pomalidomide) in combination with chemotherapy with or without another
drug (rituximab) in people with HIV-associated NHL.
Eligibility:
Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk
features.
Design:
Participants will undergo screening. They will have a physical exam. They will have blood and
urine tests and tests of heart function. They may have imaging scans. Researchers will review
tissue samples of participant s tumors. In some cases, a new biopsy may be needed.
Participants will receive up to 6 cycles of treatment.
The first cycle is 26 days: Participants will take pomalidomide by mouth for 10 days. After 5
days they will start receiving chemotherapy drugs through a tube attached to a needle placed
in a vein (IV). Some participants will receive rituximab on day 5. All participants will
receive a second set of IV drugs that will last for 4 days (96 hours). They will receive
another IV drug after the previous treatment is complete.
The remaining cycles are each 21 days. Participants will take pomalidomide by mouth for the
first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each
cycle.
Screening tests will be repeated at study visits.
Follow-up visits will continue for 4 years.